The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Accretive Health's revenues will compress -8.9% and EPS will shrink -47.1%.
The average estimate for revenue is $237.0 million. On the bottom line, the average EPS estimate is $0.09.
Last quarter, Accretive Health recorded revenue of $223.1 million. GAAP reported sales were 1.9% higher than the prior-year quarter's $218.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.06. GAAP EPS of $0.03 for Q3 were 57% lower than the prior-year quarter's $0.07 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 20.7%, 170 basis points worse than the prior-year quarter. Operating margin was 2.0%, 360 basis points worse than the prior-year quarter. Net margin was 1.2%, 210 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $950.6 million. The average EPS estimate is $0.25.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 33 members out of 40 rating the stock outperform, and seven members rating it underperform. Among 13 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 10 give Accretive Health a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Accretive Health is outperform, with an average price target of $13.20.
Is Accretive Health the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Accretive Health to My Watchlist.